Zev A. Wainberg
Led NAPOLI 3, the trial that made NALIRIFOX a first-line option for metastatic pancreatic cancer.
Overview
Zev Wainberg was principal investigator of NAPOLI 3, which showed NALIRIFOX (liposomal irinotecan, oxaliplatin, fluorouracil) improves survival over gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer, and has led FGFR2b (bemarituzumab) and claudin 18.2 trials in gastric cancer. He co-directs GI oncology at UCLA and runs early-phase GI trials.
Pages like this
not linked directly; found by shared links- PersonThierry Conroy
Shares Pancreatic ductal adenocarcinoma and the tags pancreatic, trialist.
- ProductBemarituzumab
Shares FORTITUDE-101, FGFR2, Gastric & gastro-oesophageal junction cancer.
- PersonTanios Bekaii-Saab
Shares NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer, FGFR2, Pancreatic ductal adenocarcinoma.
- ProductGemcitabine + nab-paclitaxel
Shares NAPOLI 3, Pancreatic ductal adenocarcinoma.
- PersonMitsuru Sasako
Shares Gastric & gastro-oesophageal junction cancer and the tag gastric.
- PersonDaniel D. Von Hoff
Shares Pancreatic ductal adenocarcinoma and the tag pancreatic.
- ProductNALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)
Shares NAPOLI 3, Pancreatic ductal adenocarcinoma.
- PersonRichard S. Finn
Shares UCLA Jonsson Comprehensive Cancer Center and the tag trialist.